FDA Clearance Tracker · K260545
CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System; CONTOUR® NEXT ONE Blood Glucose Monitoring System
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 27, 2026
Substantially Equivalent
Time to decision
190 days
Received Feb 18, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K260545
- Device name
- CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System; CONTOUR® NEXT ONE Blood Glucose Monitoring System
- Applicant
- Ascensia Diabetes Care
- Applicant location
- Valhalla, NY
- Received
- Feb 18, 2026
- Decided
- Aug 27, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1345
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NBW. The earliest in FDA's data is K010403, decided Mar 26, 2001.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260545
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Ascensia Diabetes Care
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250813 · Decided May 14, 2025 · 58 days after receipt
Device type: Multiple Use Blood Lancet For Single Patient Use Only (QRL) · General & Plastic Surgery
K241787 · Decided Aug 27, 2024 · 67 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
- MICROLET®NEXT Lancet510(k)
K241810 · Decided Aug 15, 2024 · 55 days after receipt
Device type: Single Use Only Blood Lancet Without An Integral Sharps Injury Prevention Feature (QRK) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.